Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation
| Autor: | E.C.G. van Geffen, Antoine C. G. Egberts, Jacqueline G. Hugtenburg, Eibert R. Heerdink, R. Van Hulten |
|---|---|
| Přispěvatelé: | Clinical pharmacology and pharmacy, APH - Health Behaviors & Chronic Diseases, APH - Quality of Care, CCA - Cancer Treatment and quality of life, Population-based studies of drug treatment: from molecule to patient outcomes, Universiteit Utrecht, Dep Farmaceutische wetenschappen |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Time Factors Epidemiology Nausea Serotonin reuptake inhibitor Citalopram Biomedische technologie en medicijnen behavioral disciplines and activities Farmacie/Biofarmaceutische wetenschappen (FARM) Fluoxetine Surveys and Questionnaires medicine Humans Pharmacology (medical) Adverse effect Psychiatry Netherlands Ziekenhuisstructuur en organisatie van de gezondheidszorg Pharmacology business.industry Depression digestive oral and skin physiology Farmacie(FARM) General Medicine Middle Aged medicine.disease Paroxetine Discontinuation Substance Withdrawal Syndrome Quality of Life Female Public Health medicine.symptom business Anxiety disorder Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Van Geffen, E C G, Hugtenburg, J G, Heerdink, E R, Van Hulten, R P & Egberts, A C G 2005, ' Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice : Tapering versus abrupt discontinuation ', European Journal of Clinical Pharmacology, vol. 61, no. 4, pp. 303-307 . https://doi.org/10.1007/s00228-005-0921-x European Journal of Clinical Pharmacology, 61(4), 303-307. Springer Verlag |
| ISSN: | 0031-6970 |
| DOI: | 10.1007/s00228-005-0921-x |
| Popis: | Objective: Tapering of selective serotonin reuptake inhibitor (SSRI) therapy, as opposed to abrupt discontinuation, has been recommended by several guidelines and in the literature in order to diminish the occurrence of discontinuation symptoms. However, the evidence of a favourable effect of tapering is limited, and it is unclear how patients ought to discontinue SSRIs in daily life. The aim of this study was to examine the way in which patients discontinue SSRI therapy in clinical practice and to compare the effect of tapering with that of abrupt discontinuation on the occurrence of discontinuation symptoms. Methods: Patients (n=74) who recently discontinued SSRI therapy completed a questionnaire containing questions about discontinuation symptoms (DESS events), the prescribed SSRI, reasons for discontinuation, way of discontinuation, knowledge of discontinuation symptoms, impact on daily life and patient counseling and education. The number of DESS events was compared among groups (abrupt discontinuation versus tapering; age; male versus female; paroxetine versus other SSRIs; knowledge of discontinuation symptoms at start of therapy versus lack of knowledge). Results: A total of 66 patients were eligible for analysis. Of all patients ending SSRI therapy, 21% abruptly discontinued therapy. There was a significant difference in the number of DESS events between abrupt discontinuation and tapering of SSRI therapy (12.0 versus 5.9). There was also a tendency for an adverse effect of lack of knowledge of discontinuation symptoms at the start of therapy on the number of DESS events (8.9 versus 5.5). Conclusion: One in five patients abruptly discontinued their SSRI therapy in clinical practice. Abrupt discontinuation caused a larger increase in the number of discontinuation symptoms than tapering. We therefore advise tapering SSRI therapy in clinical practice to prevent unnecessary adverse effects of discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink